Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on May 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on April 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 5/1/2026.
- Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 5/1/2026.
- Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 5/1/2026.
- Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 5/1/2026.
- Sold $1,001 – $15,000 in shares of SS&C Technologies (NASDAQ:SSNC) on 5/1/2026.
- Purchased $1,001 – $15,000 in shares of Wayfair (NYSE:W) on 5/1/2026.
- Purchased $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 5/1/2026.
- Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 5/1/2026.
- Purchased $1,001 – $15,000 in shares of Sensata Technologies (NYSE:ST) on 5/1/2026.
- Purchased $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 5/1/2026.
BridgeBio Pharma Stock Performance
NASDAQ BBIO traded up $1.27 during trading on Tuesday, hitting $65.95. The stock had a trading volume of 2,409,937 shares, compared to its average volume of 2,780,098. BridgeBio Pharma, Inc. has a 12 month low of $31.77 and a 12 month high of $84.94. The company’s 50-day moving average price is $71.23 and its two-hundred day moving average price is $71.47. The company has a market capitalization of $12.92 billion, a PE ratio of -17.63 and a beta of 1.02.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the stock. Wells Fargo & Company increased their price objective on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. HC Wainwright upped their target price on BridgeBio Pharma from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Monday. JPMorgan Chase & Co. increased their price target on BridgeBio Pharma from $89.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, March 10th. William Blair began coverage on BridgeBio Pharma in a research report on Tuesday, March 10th. They set an “outperform” rating on the stock. Finally, TD Cowen reiterated a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Twenty-four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $88.19.
Get Our Latest Stock Report on BBIO
Insiders Place Their Bets
In other news, CAO Maricel Apuli sold 2,000 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $71.58, for a total value of $143,160.00. Following the transaction, the chief accounting officer directly owned 134,115 shares of the company’s stock, valued at $9,599,951.70. The trade was a 1.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $74.62, for a total value of $2,984,800.00. Following the sale, the chief executive officer directly owned 615,686 shares of the company’s stock, valued at $45,942,489.32. This represents a 6.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 239,084 shares of company stock valued at $16,615,979 over the last quarter. Company insiders own 14.23% of the company’s stock.
Hedge Funds Weigh In On BridgeBio Pharma
Several institutional investors and hedge funds have recently modified their holdings of BBIO. L & S Advisors Inc bought a new position in BridgeBio Pharma in the third quarter valued at about $877,000. Principal Financial Group Inc. increased its holdings in BridgeBio Pharma by 23.0% in the 3rd quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock worth $65,829,000 after purchasing an additional 236,885 shares in the last quarter. TD Asset Management Inc bought a new position in BridgeBio Pharma in the 3rd quarter valued at approximately $4,620,000. Central Pacific Bank Trust Division acquired a new position in shares of BridgeBio Pharma during the fourth quarter worth $789,000. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of BridgeBio Pharma by 14,211.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 994,220 shares of the company’s stock valued at $77,783,000 after buying an additional 987,273 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.
Key BridgeBio Pharma News
Here are the key news stories impacting BridgeBio Pharma this week:
- Positive Sentiment: BridgeBio submitted an NDA to the FDA for encaleret in ADH1, a meaningful regulatory milestone that brings the drug closer to potential approval. The company also said Phase 3 CALIBRATE results showed rapid and durable benefits across key clinical measures. Article: BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
- Positive Sentiment: HC Wainwright lifted its 2027 earnings estimates for BridgeBio and reiterated a Buy rating with a $110 price target, signaling improved confidence in the company’s longer-term earnings outlook. Article: Analysts Offer Insights on Healthcare Companies: Vericel (VCEL) and BridgeBio Pharma (BBIO)
- Positive Sentiment: HC Wainwright also raised its Q2, Q3, and Q4 2027 EPS forecasts for BBIO, reinforcing the view that BridgeBio’s pipeline could translate into stronger future profitability. Article: Analysts Offer Insights on Healthcare Companies: Vericel (VCEL) and BridgeBio Pharma (BBIO)
- Positive Sentiment: The company’s recent acoramidis data in ATTR-CM continued to show disease-modifying effects and fewer heart-failure worsening events, which may support commercial expectations for the drug. Article: Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
- Positive Sentiment: BridgeBio announced a $500 million share repurchase program, a shareholder-friendly move that can help support the stock and signal management confidence. Article: BridgeBio Pharma Announces $500 Million Stock Repurchase Program
- Negative Sentiment: CEO Neil Kumar sold 40,000 shares in a pre-arranged 10b5-1 transaction, which may weigh on sentiment even though it was planned in advance. Article: SEC Form 4 insider sale by Neil Kumar
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
BridgeBio Pharma Company Profile
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Featured Stories
- Five stocks we like better than BridgeBio Pharma
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
